How will evolving capital markets trends and shifting SEC priorities shape IPO execution and issuer readiness in 2026? A recent CLE webinar analyzed 2025’s pivotal market, legal, and regulatory developments and looked ahead...more
3/17/2026
/ Artificial Intelligence ,
Capital Markets ,
Continuing Legal Education ,
Corporate Governance ,
Disclosure Requirements ,
Initial Public Offering (IPO) ,
Investors ,
Non-GAAP Financial Measures ,
Publicly-Traded Companies ,
Regulatory Oversight ,
Securities Regulation
For some biotechs, AI isn’t just a tool; it’s their entire thesis.
Either way, if you haven’t started experimenting, you’re behind the curve.
But it’s not too late. Chelsea Anderson, Rob Freedman, Matthew Rossiter, Vanessa...more
Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets. As scrutiny on life sciences communications increases,...more
12/23/2025
/ Clinical Trials ,
Corporate Governance ,
Data-Sharing ,
Disclosure Requirements ,
Food and Drug Administration (FDA) ,
Form 8-K ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Public Communications ,
Publicly-Traded Companies ,
Regulatory Requirements ,
Securities and Exchange Commission (SEC)
For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program. ...more
Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging. In the video above, Chelsea Anderson, Rob Freedman, and Amanda L. Rose share what life sciences...more
What do life sciences companies need to know about capital markets heading into 2026?
While momentum has shifted, the markets are showing more confidence, so preparation is key for companies that want to seize opportunities...more
The journey to becoming a public company requires strategic planning and thoughtful coordination. While the IPO process typically spans six months or more, laying the groundwork should begin much earlier to ensure a smooth...more
For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword....more
1/6/2025
/ Capital Raising ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Initial Public Offering (IPO) ,
Investors ,
Life Sciences ,
Material Nonpublic Information ,
Medical Research ,
Pharmaceutical Industry ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies
When it comes to disclosing clinical trial data in the biotechnology arena, in particular for public biotech companies, timing is everything. Disclosures are not just about when to reveal the information, but also what is...more
1/6/2025
/ Annual Reports ,
Biotechnology ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Financial Industry Regulatory Authority (FINRA) ,
Food and Drug Administration (FDA) ,
Form 10-K ,
Form 10-Q ,
Life Sciences ,
Pharmaceutical Industry ,
Securities and Exchange Commission (SEC)